Tag: Disease modifying therapies

The human brain shrinks at an estimated rate of 5% per decade after age 40, a process that can be accelerated by neurodegenerative diseases [1.3.2, 1.3.3]. The pressing question for many is: what medication is used to slow down brain atrophy? This article examines current and emerging pharmacological options.

Over 30 years of research have demonstrated that multiple sclerosis (MS) is an inflammatory, immune-mediated disease, creating a rationale for the use of immunosuppressive therapy. A wide range of immunosuppressants are used in the treatment of multiple sclerosis, from older chemotherapy agents to newer, highly-targeted monoclonal antibodies and oral drugs.

Pain affects over 60% of people with multiple sclerosis (MS), highlighting the critical need to address the underlying causes of damaged nerves. Understanding **what medication is used for MS nerves** is crucial for managing symptoms and slowing disease progression.